ADVL1411; A Phase 1/2 Study of BMN 673 an Oral Poly(ADP-Ribose) Polymerase Inhibitor Plus Temozolomide in Children With Refractory or Recurrent Malignancies
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
This phase I/II trial studies the side effects and best dose of talazoparib and temozolomide and to see how well they work in treating younger patients with tumors that have not responded to previous treatment (refractory) or have come back (recurrent).
Description
The purpose of this study is to test the experimental drug combination of BMN 673 and temozolomide in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy.
Details
| Condition | Cancer |
|---|---|
| Age | 1years - 30years |
| Clinical Study Identifier | TX4710 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.